-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sibutramine is a stimulant drug that was originally developed as an appetite suppressant for the treatment of obesity.
It has been marketed under various brand names, such as Redux, Meridia, and Obestin-30, and has been available in a number of countries, including the United States, Europe, and Australia.
However, due to concerns about its safety and effectiveness, sibutramine has been withdrawn from the market in many countries.
The safety of sibutramine has been a subject of controversy and concern for many years.
Studies have shown that sibutramine can increase the risk of serious cardiovascular events, such as heart attack and stroke, particularly in patients who have a history of cardiovascular disease or who are taking other medications that affect the cardiovascular system.
The risk of these events appears to be increased at higher doses of sibutramine and in patients who have a history of cardiovascular disease.
In addition, sibutramine has been associated with a number of other side effects, such as hypertension (high blood pressure), tachycardia (rapid heart rate), and dry mouth.
As a result of these concerns, the use of sibutramine has been restricted or banned in many countries.
In the United States, for example, the Food and Drug Administration (FDA) requested that the manufacturer of sibutramine, Abbott Laboratories, withdraw the drug from the market in 2010 due to the risk of cardiovascular events.
The company complied with this request, and sibutramine is no longer available in the United States.
Despite the restrictions on the use of sibutramine, it is still available in some countries, and some individuals may still be taking the drug.
It is important for individuals who are taking sibutramine to be aware of the potential risks associated with the drug and to consult with their healthcare provider if they have any concerns.
In conclusion, the safety of sibutramine has been a subject of concern for many years due to the risk of serious cardiovascular events and other side effects.
The use of sibutramine has been restricted or banned in many countries, and individuals who are taking the drug should be aware of the potential risks and consult with their healthcare provider if they have any concerns.
